PHP
ASMB icon

Parkman Healthcare Partners’s Assembly Biosciences ASMB Stock Holding History

Parkman Healthcare Partners’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.4M Buy
411,227
+161,870
+65% +$4.62M 1.18% 27
2025
Q4 		$8.48M Sell
249,357
-1,624
-0.6% -$52.3K 0.81% 42
2025
Q3 		$6.43M Buy
+250,981
New +$5.51M 0.67% 56

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Parkman Healthcare Partners's ASMB Position: Q1 2026 in Review

Parkman Healthcare Partners increased its Assembly Biosciences (ASMB) stake by 65% in Q1 2026, buying an estimated $4.62M and bringing the position to 411,227 shares worth $11.4M. The position accounts for 1.18% of the portfolio, ranked #27.

Parkman Healthcare Partners first reported a position in ASMB in Q3 2025 and has held it in 3 quarters since. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • Parkman Healthcare Partners held 411,227 shares of Assembly Biosciences worth $11.4M as of Q1 2026.
  • Parkman Healthcare Partners bought 161,870 Assembly Biosciences shares in Q1 2026, an estimated $4.62M.
  • Assembly Biosciences made up 1.18% of Parkman Healthcare Partners's portfolio in Q1 2026, its #27 holding.
  • Parkman Healthcare Partners first reported a position in Assembly Biosciences in Q3 2025 and has held it in 3 quarters since.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.